mezigitamab
Royalty Market Accelerates with XOMA Biotech Acquisitions and OrbiMed’s Major Fundraise
royalty acquisition; XOMA Royalty; biotech M&A; OrbiMed; biopharma financing; mezigitamab; Turnstone Biologics; HilleVax; LAVA Therapeutics; contingent value rights; life sciences investment